<DOC>
	<DOCNO>NCT02204306</DOCNO>
	<brief_summary>In gastric cancer patient treat 5-FU cisplatin , high tumor TS level associate less favorable response ( 29 % vs. 68 % ; p=0.024 ) . Similarly , study patient treat high dose 5-FU , patient high TS expression response rate 12.5 % . Conversely response rate 92.9 % observed patient low tumor TS expression . A longer statistically significant survival advantage observe patient TSER*2 allele compare TSER*3/*3 patient . Additionally , review Patel et al . identify approximately 20 gastric cancer study find positive association TSER genotype clinical response ( either direction ) . Therefore , primary goal proposal prospectively genotype patient , select patient `` good risk '' TSER genotype ( TSER*2*/*2 *2/*3 ) treat standard 5-FU contain regimen ( FOLFOX ) order improve clinical outcome , randomize patient `` poor risk '' TSER genotype ( *3/*3 ) either standard 5-FU contain regimen another non-5-FU-based regimen ( docetaxel/cisplatin ) .</brief_summary>
	<brief_title>Genotype Guided Chemotherapy Gastric Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Patients must histologically cytologically confirm metastatic adenocarcinoma stomach . 2 . Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan . See section 9.2 evaluation measurable disease . 3 . No prior therapy metastatic disease . Prior neoadjuvant adjuvant therapy permit disease free interval longer 12 month . 4 . Age 18 70 year . Because dose adverse event data currently available use regimens patient &lt; 18 year age , child exclude study . 5 . Life expectancy great 3 month . 6 . ECOG performance status &lt; 2 ( Karnofsky &gt; 60 % ; see Appendix A ) . 7 . Patients must normal organ marrow function define : Leukocytes &gt; 3,000/microliter Absolute neutrophil count &gt; 1,500/microliter Platelets &gt; 100,000/microliter Total bilirubin &lt; 1.5 x ULN AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 x ULN liver metastases &lt; 5 x ULN know liver metastasis Creatinine clearance &lt; 1.5 x ULN 8 . Not pregnant . Not breast feeding . If patient partner childbearing potential , couple use adequate birth control accordance local IRB policy : For woman childbearing potential : Patient must negative blood pregnancy test . If sexually active , woman must either postmenopausal ( age 50 menstrual period one year , blood FSH level postmenopausal range ) OR agree use appropriate contraceptive measure duration study 21 day stop study treatment . The birth control method woman acceptable study : ( 1 ) surgical sterilization ( previous removal uterus ovary tubal ligation ) OR ( 2 ) intrauterine device ( IUD ) , ( 3 ) double barrier method , ( 4 ) oral contraceptive . For men : Medically acceptable contraceptive include : ( 1 ) surgical sterilization , ( 2 ) condom use spermicide . If female partner become pregnant patient treatment within 21 day stop treatment , study physician must inform . 9 . Ability understand willingness sign write informed consent document . 1 . Patients may receive chemotherapy agent . 2 . Patients know active brain metastasis . Patients treat brain metastasis permit stable steroid least 30 day . A screening head CT/MRI require asymptomatic patient protocol . 3 . History allergic reaction 5FU , oxaliplatin , docetaxel , cisplatin . 4 . Uncontrolled intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . 5 . Patients immune deficiency increase risk lethal infection treat marrowsuppressive therapy . Therefore , HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>